3 U.S. Healthcare Stocks For Investors Seeking Safety and Steady Cash Flow

Risk feels higher, yet U.S. Treasury yields are hugging recent lows and investors are again paying up for resilience. That mix of caution and selective optimism can reward those who focus on financially solid, lower volatility large caps before the crowd fully rotates. This article walks through three U.S. stocks from a defensive screener that appear well positioned or relatively insulated based on the latest macro shocks, and explains why their profiles matter now.

The three stocks highlighted below are only a starting sample from this idea. The full screen pulled up 8 more large U.S. companies with similar defensive traits and equally compelling stories that are not covered here.

To see the whole field and sharpen your own short list, head straight into the Defensive, high-quality U.S. large-cap stocks screener to identify, compare, and analyze the highest conviction opportunities that match your risk profile.

CVS Health (CVS)

Overview: CVS Health is an integrated U.S. healthcare group that combines insurance, pharmacy benefit management, and retail pharmacies to deliver recurring care services.

Operations: CVS Health generates about US$200.5b from Health Services, US$143.8b from Health Care Benefits, and US$139.7b from Pharmacy & Consumer Wellness, almost entirely in the United States.

Market Cap: US$120.8b

CVS Health: Defensive Cash Flows In A Risk-Off Market

CVS Health fits this defensive large-cap screen because its integrated healthcare model leans on recurring insurance premiums and prescription activity that tend to hold up when investors are crowding into lower-volatility cash generators.

Recent quarters have been bumpy for CVS Health as it absorbs the financial impact of its healthcare pivot, and the pressure point is clear in one line item.

"The decline is contributed largely to a $1.1 billion charge connected with its Medicare and Individual Exchange businesses and a whopping $1.2 billion restructuring charge for store closures."

What really matters for this screen is how one unresolved pressure on future healthcare profitability ultimately shapes the recovery in margins and cash generation.

That margin reset is only the starting point, and the full narrative for CVS Health shows how CVS Health could turn restructuring pain into accelerating cash generation and a sturdier earnings mix.

Humana (HUM)

Overview: Humana is a major U.S. health insurer focused on Medicare Advantage plans and senior-focused care services through its CenterWell operations.

Operations: Humana generates about US$139.7b from Insurance and US$24.7b from CenterWell, with virtually all US$145.8b of revenue coming from the United States.

Market Cap: US$50.6b

Humana matters for this defensive screen because recurring Medicare premiums and senior-focused care create a relatively durable revenue stream when investors lean toward lower volatility healthcare exposure.

"Regulators are placing greater emphasis on whether documentation fully supports diagnoses and whether medical necessity determinations align precisely with program rules."

For shareholders, the key question is what happens to Medicare Advantage profitability if a single unseen pressure on quality ratings and compliance costs shifts the earnings glidepath.

That hidden pressure point is exactly where the full narrative for Humana picks up, mapping how Humana’s earnings story could shift as regulation, ratings and member mix start decoupling.

Stryker (SYK)

Overview: Stryker is a large medical technology company that supplies surgical equipment and orthopedic implants to hospitals and healthcare providers worldwide.

Operations: Stryker generates about US$9.7b from Orthopaedics and US$16.1b from MedSurg and Neurotechnology, primarily serving healthcare customers in the United States.

Market Cap: US$117.8b

Stryker fits this defensive, high-quality large-cap screen because hospital demand for joint replacements and surgical equipment tends to be steady, which can appeal to investors looking for lower volatility healthcare exposure as money moves toward perceived safety.

"Expanding use of Stryker’s Mako platform, including record installations, broader procedure coverage such as shoulder and advanced hip or revision, and the rollout of Mako RPS for handheld knee robotics, supports a larger orthopedic addressable market and can lift revenue and associated service earnings over time."

The real hinge for Stryker is what happens to margins and cash generation if one key assumption behind that equipment cycle shifts.

If that assumption is wrong or accelerating, the full narrative for Stryker explains how Stryker’s robotics story, pricing power, and risks fit together.

Seeking Fresh Alternatives Before They Fly?

Fresh ideas move first. Once momentum builds, entry points can get caught chasing prices instead of spotting them early while they are under the radar. For now, act promptly.

• Pinpoint income workhorses that aim to keep paying when others are dropping by scanning the curated list of 5 dividend fortresses.
• Track early movers riding AI infrastructure momentum before the crowd fully wakes up by running the focused 55 AI infrastructure stocks.
• Hunt for resilient operators with steady financial footing that can stay in the game longer through the curated list of solid balance sheet and fundamentals (25 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com